dc.contributor
Institut Català de la Salut
dc.contributor
[Albanell J] Hospital del Mar Research Institute Barcelona, Depatment of Medical Oncology, Hospital del Mar, Barcelona, Spain. Universitat Pompeu Fabra, Barcelona, Spain. Centro de Investigación Biomédica en Red de Oncología (CIBERONC-ISCIII), Madrid, Spain. [Gámez Pozo A] Translational Oncology Lab, University Hospital La Paz - IdiPAZ, Madrid, Spain. [Arteaga CL] UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX, USA. [Bellet M] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Rojo F, González A] Hospital del Mar Research Institute Barcelona, Depatment of Medical Oncology, Hospital del Mar, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Arteaga, Carlos
dc.contributor.author
Rojo, Federico
dc.contributor.author
Gonzalez-Perez, Abel
dc.contributor.author
Albanell, Joan
dc.contributor.author
Gamez-Pozo, Angelo
dc.contributor.author
Bellet Ezquerra, Meritxell
dc.date.accessioned
2025-10-25T05:37:25Z
dc.date.available
2025-10-25T05:37:25Z
dc.date.issued
2025-08-12T07:57:37Z
dc.date.issued
2025-08-12T07:57:37Z
dc.date.issued
2025-06-20
dc.identifier
Albanell J, Gámez Pozo A, Arteaga CL, Bellet M, Rojo F, González A, et al. Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial. npj Breast Cancer. 2025 Jun 20;11:59.
dc.identifier
http://hdl.handle.net/11351/13527
dc.identifier
10.1038/s41523-025-00777-0
dc.identifier
001512768100002
dc.identifier.uri
http://hdl.handle.net/11351/13527
dc.description.abstract
Biomarkers; Hormone receptor-positive; Advanced breast cancer
dc.description.abstract
Biomarcadores; Cáncer de mama avanzado; Receptor hormonal positivo
dc.description.abstract
Biomarcadors; Càncer de mama avançat; Receptor hormonal positiu
dc.description.abstract
Currently, there are no clinically actionable biomarkers to predict patient to cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) plus endocrine therapy for hormone receptor (HR)[+]/ human epidermal growth factor receptor 2 (HER2)[-] advanced breast cancer (ABC). Herein, we report an exploratory biomarker substudy (transFAL) from a subset of patients included in PARSIFAL, a phase II randomized clinical trial that evaluated first-line palbociclib plus fulvestrant or letrozole for HR[+]/HER2[−] ABC. No definitive biomarkers were discovered, however, worse outcomes were found with CDK6 postivity (p = 0.008), ER negativity (p = 0.008), high Ki67 (p = 0.04), and TP53 mutation (p = 0.04). ctDNA density (p = 0.036) and number of mutations (p = 0.033) at baseline were significantly higher for resistant patients. Our study reveals future directions to explore in the goal to determine biomarkers of response to CDK4/6i.
dc.format
application/pdf
dc.publisher
Nature Portfolio
dc.relation
npj Breast Cancer;11
dc.relation
https://doi.org/10.1038/s41523-025-00777-0
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Marcadors bioquímics
dc.subject
Proteïnes quinases - Inhibidors - Ús terapèutic
dc.subject
Mama - Càncer - Tractament
dc.subject
Quimioteràpia combinada
dc.subject
CHEMICALS AND DRUGS::Biological Factors::Biomarkers
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors
dc.subject
Other subheadings::Other subheadings::/therapeutic use
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas
dc.subject
Otros calificadores::Otros calificadores::/uso terapéutico
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
dc.title
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
